Aquestive Therapeutics
AQST
114 hedge funds and large institutions have $154M invested in Aquestive Therapeutics in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 33 reducing their positions, and 22 closing their positions.
212% more call options, than puts
Call options by funds: $1.89M | Put options by funds: $605K
39% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 33
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
3% less funds holding
Funds holding: 117 → 114 (-3)
3.79% less ownership
Funds ownership: 51.37% → 47.57% (-3.8%)
34% less capital invested
Capital invested by funds: $232M → $154M (-$78M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$3.02M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.87M |
| 3 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$2.31M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.52M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$13.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$3.41M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$2.91M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.26M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$2.13M |
AQST Hedge Fund Activity: Q4 2024 in Review
114 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2024, worth a combined $154M — down 34% from $232M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AQST and 21 opened new positions — a net loss of 1 holder — while 33 trimmed existing stakes and 46 added.
The largest buyer was Goldman Sachs, adding an estimated $3.02M. The largest seller was VR Adviser, cutting an estimated $13.5M.
- 114 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2024, down from 117 in Q3 2024.
- Funds reported $154M of Aquestive Therapeutics stock for Q4 2024, down 34% quarter-over-quarter.
- 21 funds opened new Aquestive Therapeutics positions in Q4 2024 and 22 closed out, a net change of -1 holder.
- The largest Aquestive Therapeutics buyer in Q4 2024 was Goldman Sachs, an estimated $3.02M added.
- The largest Aquestive Therapeutics seller in Q4 2024 was VR Adviser, an estimated $13.5M sold.
Based on aggregated 13F filings for Q4 2024.